🇺🇸 FDA
Patent

US 10047104

Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

granted A61PA61P1/02A61P1/04

Quick answer

US patent 10047104 (Bicyclic heterocyclyl derivatives as IRAK4 inhibitors) held by Aurigene Discovery Technologies Limited expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aurigene Discovery Technologies Limited
Grant date
Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P1/02, A61P1/04, A61P1/16, A61P1/18